"Neoadjuvant Therapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, immunotherapy, hyperthermia, etc.) that precedes a necessary second modality of treatment.
| Descriptor ID |
D020360
|
| MeSH Number(s) |
E02.186.450
|
| Concept/Terms |
Neoadjuvant Therapy- Neoadjuvant Therapy
- Neoadjuvant Therapies
- Therapies, Neoadjuvant
- Therapy, Neoadjuvant
- Neoadjuvant Treatment
- Neoadjuvant Treatments
- Treatment, Neoadjuvant
- Treatments, Neoadjuvant
|
Below are MeSH descriptors whose meaning is more general than "Neoadjuvant Therapy".
Below are MeSH descriptors whose meaning is more specific than "Neoadjuvant Therapy".
This graph shows the total number of publications written about "Neoadjuvant Therapy" by people in this website by year, and whether "Neoadjuvant Therapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 1 | 1 | 2 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 2 | 2 |
| 2007 | 1 | 4 | 5 |
| 2009 | 0 | 1 | 1 |
| 2010 | 2 | 3 | 5 |
| 2011 | 0 | 3 | 3 |
| 2012 | 2 | 5 | 7 |
| 2013 | 0 | 2 | 2 |
| 2014 | 1 | 1 | 2 |
| 2015 | 1 | 9 | 10 |
| 2016 | 2 | 4 | 6 |
| 2017 | 1 | 5 | 6 |
| 2018 | 1 | 2 | 3 |
| 2019 | 0 | 2 | 2 |
| 2020 | 0 | 3 | 3 |
| 2021 | 2 | 2 | 4 |
| 2022 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neoadjuvant Therapy" by people in Profiles.
-
The use of oncolytic virotherapy in the neoadjuvant setting. J Immunother Cancer. 2022 04; 10(4).
-
Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2022 04 01; 28(7):1345-1352.
-
Late cardiac toxicity of neo-adjuvant chemoradiation in esophageal cancer survivors: A prospective cross-sectional pilot study. Radiother Oncol. 2022 02; 167:72-77.
-
Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma. Cell Rep Med. 2021 10 19; 2(10):100411.
-
Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma. Cell Rep Med. 2021 10 19; 2(10):100426.
-
Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial. Int J Med Sci. 2021; 18(10):2245-2250.
-
Commentary: Durable activity of a tyrosine kinase inhibitor in lung cancer. J Thorac Cardiovasc Surg. 2021 02; 161(2):446-447.
-
Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer. Clin Cancer Res. 2020 07 01; 26(13):3117-3125.
-
Modeling rectal cancer to advance neoadjuvant precision therapy. Int J Cancer. 2020 09 01; 147(5):1405-1418.
-
Polysomy is associated with poor outcome in 1p/19q codeleted oligodendroglial tumors. Neuro Oncol. 2019 09 06; 21(9):1164-1174.